4/A: AVNS CEO Pacitti Corrects Stock Option Grant

AVANOS MEDICAL, INC. CEO David Pacitti filed an amended Form 4 to correct an error in previously reported stock option grants.

Summary

• CEO David Pacitti received an award of 101,341 time-based restricted share units (TRSUs) and 239,354 employee stock options on March 13, 2026.
• The TRSUs will vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029.
• The employee stock options will vest 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029.
• This Form 4/A corrects an error in a previous Form 4/A filing from April 1, 2026, which erroneously added to the number of stock options; the original Form 4 filed on March 17, 2026, was accurate.
• Following these transactions, Pacitti beneficially owns 343,388 shares of common stock and 239,354 employee stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as largely neutral, as it primarily serves to correct an administrative error. The underlying equity awards are a positive for executive alignment, but the need for a correction introduces a minor negative.

Positives

• CEO David Pacitti received a significant equity award, aligning his interests with shareholders through long-term vesting schedules.
• The company demonstrated transparency and commitment to regulatory compliance by promptly correcting a previous filing error.

Negatives

• A previous administrative error in reporting stock options required an amendment, indicating a minor oversight in the initial filing process.

Future Outlook

The filing details executive equity awards with multi-year vesting schedules, indicating a long-term incentive structure for the CEO, aligning his future performance with shareholder value creation through March 2029.

Industry Context

StockSavvy.ai notes that executive equity awards, particularly those with multi-year vesting schedules like the TRSUs and stock options granted to CEO David Pacitti, are standard practice in the medical device industry. This structure aims to incentivize long-term performance and retention, aligning executive interests with sustained company growth and shareholder returns, a common strategy among peers like Medtronic or Stryker.

Comparison to Industry Standards

• The grant of time-based restricted share units and stock options to a CEO is a common executive compensation practice across industries, including medical devices.
• While specific award sizes vary by company size, performance, and individual executive roles, the multi-year vesting schedule (3-year for TRSUs, 3-year for options) is consistent with typical long-term incentive plans designed to retain key executives and align their interests with long-term shareholder value.
• Similar vesting schedules are observed in compensation packages at companies like Boston Scientific or Zimmer Biomet for their executive leadership.

Stakeholder Impact

• Shareholders: The correction ensures accurate public record of executive compensation. The equity awards align CEO interests with shareholder value creation.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Vesting of 1/3 of TRSUs and 30% of stock options on March 13, 2027.
• Vesting of 1/3 of TRSUs and 30% of stock options on March 13, 2028.
• Vesting of 1/3 of TRSUs and 40% of stock options on March 13, 2029.
• Expiration of employee stock options on March 13, 2036.

Key Dates

Recommendation

This filing is an administrative correction of an executive equity award and does not contain new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The underlying equity awards are a standard practice for executive compensation, aligning the CEO's interests with long-term shareholder value, which is generally a neutral to slightly positive factor. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a basis for a 'buy' or 'sell' decision.

Keywords

AVANOS MEDICAL, AVNS, David Pacitti, SEC Form 4/A, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Equity Award, Corporate Governance